AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
The Cancer News Team
Published Articles (90)
August 6, 2026
Most people know that tobacco causes cancer, but far fewer know that alcohol does, too. In the United States alone, alcohol contributes to nearly 100,000 new cancer diagnoses and approximately 20,000 cancer deaths every year.
June 19, 2026
VIKTORIA-1 data show gedatolisib roughly doubled PFS versus alpelisib in PIK3CA-mutant HR+/HER2-negative advanced breast cancer — with a more favorable tolerability profile. An expert breaks down the findings.
June 16, 2026
To illustrate what a 20% survival rate looks like in practice, Force opens with a case: a 10-year-old boy brought to a rural East African hospital by his grandmother with a progressive jaw mass, intermittent fevers, and microcytic anemia.
June 13, 2026
SUCCESSOR-2 extended median PFS to 18 months with mezigdomide plus carfilzomib and dexamethasone in relapsed/refractory myeloma. An expert weighs in on what the phase 3 results mean for community practice.
June 13, 2026
WU-KONG28 and LIBRETTO-432 delivered practice-changing data at ASCO 2026 for molecularly defined NSCLC. A thoracic oncologist breaks down what sunvozertinib and selpercatinib mean for frontline and adjuvant care.
May 8, 2026
Oncologists explain why ivermectin is not a proven cancer treatment, summarizing current evidence, ongoing trials in TNBC, and how clinicians address patient misinformation.
May 1, 2026
Key insights from Dr. Paolo Tarantino on how antibody-drug conjugates are transforming solid tumor treatment, moving from late-line therapy to frontline and curative-intent strategies.
April 14, 2026
Binaytara awards $50,000 in cancer research funding through its first-ever Impact Pitch, high-energy competition advancing innovative solutions for cancer health equity.
February 24, 2026
Dr. Gentry King reviews the latest advances in hepatocellular carcinoma and biliary tract cancers, highlighting FGFR2-targeted therapy, immune checkpoint inhibitors, and evolving strategies across BCLC stages.
February 24, 2026
Dr. Rachael A. Safyan reviews evolving treatment strategies in pancreatic cancer, from neoadjuvant therapy and tumor-treating fields to RAS-targeted agents reshaping metastatic care.
February 24, 2026
Dr. David Zhen reviews major advances in neuroendocrine tumor treatment, including cabozantinib approval, earlier use of PRRT, emerging alpha-emitter radioligand therapies, and novel targeted agents.
February 24, 2026
Dr. Emerson Y. Chen reviews MATTERHORN, HERIZON-GEA-01, and DESTINY-Gastric04, highlighting perioperative nivolumab plus FLOT and next-generation HER2-directed therapies in advanced gastroesophageal cancer.
February 18, 2026
A new study suggests multicancer blood tests could shift cancer diagnoses to earlier stages. Here’s what liquid biopsy is, how MCED tests work, current FDA approvals, benefits, risks, and what patients should know.
February 17, 2026
An expert panel at Best of Hematology & Breast Cancer 2026 debates early use of bispecific antibodies versus CAR T-cell therapy in an 83-year-old patient with relapsed multiple myeloma.
February 17, 2026
Dr. Andrew J. Cowan reviews ASH 2025 updates in frontline multiple myeloma, including MRD dynamics, t(11;14), Duffy null genotype, functional high-risk disease, CD38 maintenance, and emerging bispecific strategies.
February 17, 2026
Dr. Thomas DeLoughery reviews evolving treatment strategies for immune thrombocytopenia and autoimmune hemolytic anemia, highlighting thrombopoietin agonists, BTK inhibitors, anti-CD38 antibodies, and complement-targeted therapies.
February 17, 2026
Dr. Hannah Linden reviews treatment strategies for ER-positive metastatic breast cancer after CDK4/6 inhibitors, highlighting SERDs, combination therapies, ESR1 mutation testing, and emerging imaging tools.
February 17, 2026
Dr. Vidhya Nair reviews key advances in HER2-positive breast cancer, highlighting de-escalation in early-stage disease, T-DXd in high-risk and metastatic settings, and evolving personalized treatment strategies.
February 17, 2026
Dr. Xiaowen Wang reviews evolving strategies for advanced ER-positive metastatic breast cancer, highlighting NGS timing, ESR1 and PIK3CA mutations, novel SERDs, and targeted combination therapies.
February 16, 2026
Dr. Vivian G. Oehler reviews major advances in myeloproliferative neoplasms, including pelabresib in myelofibrosis, CALR-targeted therapy in essential thrombocythemia, rusfertide in polycythemia vera, and new allosteric inhibitors in CML.